Q3 2017 Regenxbio Inc Earnings Call

8/11/2017 16:30

Llamada en conferencia Regenxbio Inc

Regenxbio Inc Conference call will be held on 08-nov-2017. During the earnings conference call's session Regenxbio Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Regenxbio Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. In AAV gene therapy, the viral genes are removed from the AAV, a small, non-pathogenic virus, creating a biological delivery vehicle called a vector. A therapeutic gene sequence is then inserted, creating a recombinant vector. Our proprietary AAV gene delivery platform (our NAV Technology Platform) consists of exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Our mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing gene therapy products administered directly into the body, or in vivo, based on our NAV Technology Platform.    
Leer más Llamada en conferencia

Regenxbio Inc (RGNX)

9712 Medical Center Drive, Rockville Maryland 20850, United States